New shingles vaccine candidate enters Mid-Stage trial

NCT ID NCT07311148

Ongoing ⭐️ VACCINE ⭐️ Sponsor: Guangzhou Patronus Biotech Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new shingles vaccine called LYB004 in 840 adults aged 40 and older in China. Participants receive one of four different doses of the vaccine or a placebo. The goal is to see how well the vaccine triggers an immune response and whether it is safe.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: LYB004 (recombinant zoster vaccine with VZV glycoprotein E and adjuvant)
What this could lead to: If successful, this could lead to a new shingles vaccine option for adults 40 and older, potentially offering protection with a different formulation.
What could go wrong: This is an early Phase 2 trial, so the vaccine may not produce a strong enough immune response or could have unexpected side effects. Results may not apply to all populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HERPES ZOSTER (HZ) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chickenpox varicella zoster infection herpes zoster prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HERPES ZOSTER (HZ) RECOMBINANT ZOSTER VACCINE SHINGLES VZV

Contacts and locations

Show contact details

Locations

Hengnan County Center for Disease Control and Prevention

Hengyang, Hunan, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.